Clinical Trial Update: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. [Phase 3]

View source ↗

Summary

Phase 3 trial update for elafibranor in adults with primary biliary cholangitis who had inadequate response or intolerance to ursodeoxycholic acid.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Elafibranor

Snippet

Sponsor: Ipsen | Conditions: Primary Biliary Cholangitis | Phase 3 | Status: COMPLETED